Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation - Jin, Jian; Wang, Liang; Wang, Xiao-kai; Lai, Ping-lin; Huang, Min-jun; Jin, Da-di; Zhong, Zhao-ming; Chen, Jian-ting; Bai, Xiao-chun (The Journal of surgical research, 2013)
Keywords: Adipogenesis; Adipogenesis - drug effects; Bone Density Conservation Agents - pharmacology; Bone Marrow Cells - cytology; Bone Marrow Cells - drug effects; Bone marrow fat; Cell Differentiation - drug effects; Cells, Cultured; Dose-Response Relationship, Drug; Etidronic Acid - analogs & derivatives; Etidronic Acid - pharmacology; Humans; Mechanistic Target of Rapamycin Complex 1; Mesenchymal Stromal Cells - cytology; Mesenchymal Stromal Cells - drug effects; Multiprotein Complexes - antagonists & inhibitors; Osteoclast; Osteoclasts - cytology; Osteoclasts - drug effects; Osteoprotegerin; Osteoprotegerin - analysis; RANK Ligand - analysis; Receptor activator of nuclear factor-κB ligand; Risedronate; Risedronate Sodium; Surgery; TOR Serine-Threonine Kinases - antagonists & inhibitors; Risedronate; Bone marrow fat; Osteoclast; Receptor activator of nuclear factor-κB ligand; Adipogenesis; Osteoprotegerin